Brief: Biomea Fusion Says BMF-219 Induces Complete Responses In Patients With Acute Myeloid Leukemia
24/07/2023 14:33
July 24 (Reuters) - Biomea Fusion Inc BMEA.O :
* BIOMEA FUSION INC - DOSE LEVEL 4 EXPOSURE CORRELATES WITH
INITIAL ACTIVITY SEEN IN BMF-219'S PRE-CLINICAL STUDIES
* BIOMEA FUSION INC - SAFETY PROFILE OF BMF-219 SUPPORTS
FURTHER
DOSE ESCALATION
* BIOMEA FUSION INC - ENROLLMENT FOR DOSE LEVEL 5 HAS
COMMENCED TO
EXPLORE OPTIMAL BIOLOGICAL DOSE
* BIOMEA FUSION - BMF-219 WAS GENERALLY WELL TOLERATED WITH
NO
DOSE-LIMITING TOXICITIES OBSERVED, AND NO QTC PROLONGATION
REPORTED
* BIOMEA FUSION - TRIAL DATA REVEALED 2 COMPLETE RESPONSES
OUT OF
5 RELAPSED/REFRACTORY AML PATIENTS CARRYING MENIN-DEPENDENT
MUTATIONS AT DOSE LEVEL 4
* BIOMEA FUSION INC - BOTH PATIENTS WHO ACHIEVED CRS
CONTINUE ON
BMF-219 TREATMENT
* BIOMEA FUSION INC - COMPLETION OF DOSE ESCALATION FOR
ACUTE
LEUKEMIA COHORT IS ANTICIPATED LATER THIS YEAR
Source text for Eikon: ID:nGNX1fpxtF
Further company coverage: BMEA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biomea Fusion
See all newsUS RESEARCH ROUNDUP-BlackRock, Microsoft, TransDigm Group
Brief: Biomea Fusion Announces Phase 1 Results For Bmf-650, Its Investigational Next-Generation Oral Small Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion To Announce Phase I Results For Bmf-650, Its Next-Generation Oral Small-Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion Announces Termination Of Proposed Public Offering Of Securities
Brief: Biomea Fusion Announces Completion Of Enrollment In Covalent-211 Phase Ii Trial Of Icovamenib In Insulin-Deficient Type 2 Diabetes